The DOI matches its Crossref record; 111 of the 124 references it cites were found in a registry or an index; 80 of the 161 sources its claims cite were checked for support.
What is the pipeline for future medications for obesity?
Open accessAbstract
Obesity pipeline review. Semaglutide 2.4mg results in 15-17% weight loss. Tirzepatide leads up to 22.5% WL in phase 3. Retatrutide (GLP-1/GIP/glucagon RA) progressed to phase 3 trials. Early data suggests retatrutide may lead to even greater WL than tirzepatide.
Overview
CoChat Summary
## TL;DR
This review maps the rapidly expanding obesity drug pipeline, emphasizing that combinations of entero-pancreatic hormones are producing weight loss that can approach bariatric surgery. It highlights tirzepatide as the first approved dual agonist for chronic weight management and notes several oral, dual, and triple agonists in late-phase development.
## Key findings
- Semaglutide 2.4 mg once weekly, an approved GLP-1 receptor agonist, produces 15–17% mean weight loss and has evidence of cardioprotection; the SELECT trial reported a 20% reduction in major adverse cardiovascular events (MACE) vs placebo after 39.8 months of follow-up.
- In obesity without T2D, oral semaglutide 50 mg produced 17.4% weight loss vs 1.8% with placebo at 68 weeks in OASIS-1; in T2D, it produced 9.8% weight loss vs 5.4% with oral semaglutide 14 mg and reduced HbA1c by −2.1% vs −1.3% at 68 weeks.
- Tirzepatide (dual GLP-1/GIP agonist) achieved 16–22.5% mean weight loss at 72 weeks in SURMOUNT-1 and up to 15.7% in SURMOUNT-2; in SURMOUNT-4, participants maintained/continued to lose weight, with 25.9% of placebo vs 84.1% of tirzepatide participants achieving ≥15% weight loss at 88 weeks from baseline.
- Retatrutide (triple GLP-1/GIP/glucagon agonist) produced up to 24.2% weight loss at 48 weeks in a phase 2 obesity study; 36–48% of participants on the 8 mg and 12 mg doses achieved ≥25% weight loss.
## Methods
- Narrative review of the pipeline of obesity pharmacotherapies, with a focus on entero-pancreatic hormone-based molecules and selected non-hormonal agents.
- Synthesizes data from early- and late-phase clinical trials in people with and without T2D, and also considers effects on glycaemia, liver fat content (MASLD/MASH), and cardiovascular outcomes.
- Main analysis is descriptive comparison of efficacy, safety, and development stage across agents; Not stated in the paper as a formal systematic review or meta-analysis.
## Limitations
- The paper states that the full potential benefits and risks of the new obesity pharmacotherapies still need to be better understood, and that robust cost-effectiveness data are lacking.
- It explicitly notes that cardiovascular outcome trials are still needed for several agents, including combinations of GLP-1 with other hormones and oral GLP-1 receptor agonists.
- Evident from the text: much of the pipeline relies on phase 1/2 data, press releases, or abstract data, so some reported efficacy and safety findings are preliminary (say which: evident from the text).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
66 Valid · 1 Not valid · 63 Not checked · 13 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Despite that 5–10% WL is clinically beneficial, greater WL may be required for the individual to improve or achieve remission of some obesity-related complications [7, 8].”
§ What is the pipeline for future medications for obesity? > Introduction
What the sources say
- Supportedcites [7] Timothy Garvey W. New Horizons. A new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab. 2022;107:E1339–47. source
The “Obesity, Complications, and Adiposity-based Chronic Disease” section says that the weight loss needed for clinical benefit varies by complication: 5%–10% reduces liver steatosis, while more than 10% is required to improve inflammation and fibrosis in nonalcoholic steatohepatitis. The section on using percent weight loss as a biomarker also says treatment targets should be individualized to the complications present in each patient. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [8] Tahrani AA, Morton J. Benefits of weight loss of 10% or more in patients with overweight or obesity: a review. Obesity. 2022;30:802–40. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More specifically, orforglipron is a potent partial GLP-1 RA which is biased towards G-protein activation over to β-arrestin recruitment at the GLP-1 receptor [23].”
§ What is the pipeline for future medications for obesity? > Pipeline of obesity pharmacotherapies > Orforglipron
What the sources say
- Partly supportedcites [23] Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci USA. 2020;117:29959–67. sourceExperimental — accuracy not yet measured
The Results and Discussion section (In Vitro and In Vivo Activity of LY3502970; page unavailable) describes LY3502970 as a potent partial GLP-1R agonist that stimulates cAMP accumulation without detectable β-arrestin recruitment. Our copy does not name orforglipron or establish that it is LY3502970, so it does not fully support the claim about the named drug. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, oral semaglutide 50 mg reduced the HbA1c by −2.1% at 68 weeks compared to −1.3% with oral semaglutide 14 mg (Fig. 4) [22].”
§ What is the pipeline for future medications for obesity? > Pipeline of obesity pharmacotherapies > Oral semaglutide 50 mg
What the sources say
- Partly supportedcites [22] Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402:693–704. sourceExperimental — accuracy not yet measured
The Findings and Results report greater HbA1c reduction with oral semaglutide 50 mg than with 14 mg: −2.0 versus −1.5 percentage points at week 52. The Discussion says the reductions were largely sustained through week 68, but the passages from our copy do not establish the claimed week-68 values of −2.1% and −1.3%. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, preclinical and early phase clinical trials have confirmed the therapeutic potential of entero-pancreatic hormone combinations in obesity and/or metabolic complications such as T2D [33].”
§ What is the pipeline for future medications for obesity? > Other entero-pancreatic hormones and combination of entero-pancreatic hormones in the management of obesity
What the sources say
- Supportedcites [33] Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090. source
The Introduction says that multiple preclinical studies and emerging clinical data support the therapeutic potential of combinatorial peptide therapy for metabolic disorders. The Tirzepatide section reports early-phase trials showing improvements in weight and glucose measures, including in people with T2D. The paper cautions that clinical development remains limited, but the claim concerns therapeutic potential rather than established treatment efficacy. (LLM, conf=0.91)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“as the simultaneous activation of GLP-1 and GIP receptors in preclinical models results in greater WL and glucose-lowering efficacy compared to activation of each receptor alone [38–40]”
§ What is the pipeline for future medications for obesity? > GIP agonism
What the sources say
- Supportedcites [38] Gault VA, Kerr BD, Harriott P, Flatt PR. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin Sci. 2011;121:107–17. source
In the Results section on ob/ob mice (page unavailable), the combined Lira-AcGIP preparation significantly reduced body weight, while either incretin mimetic alone did not. A separate Results section reports significantly better glucose control with the preparation than with either mimetic alone. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [39] Nørregaard PK, Deryabina MA, Tofteng Shelton P, Fog JU, Daugaard JR, Eriksson PO, et al. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Diabetes Obes Metab. 2018;20:60–8. source
- Not checked — no full text of the sourcecites [40] Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5:209ra151. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 25 with their cited sources checked
Create a free account to see all 143 claims and every source verdict.
- It may state two separate claims as one. 71
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In summary, dual and triple agonists related to GLP-1 represent significant advances in the field of diabetes treatment,167,168 demonstrating the future trend of enhancing therapeutic effects by targeting multiple biomarkers.136,169,170”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the Nutrient Stimulated Hormones being targeted have effects on muscle protein synthesis and even energy expensiture [42–44].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MariTide is a monthly subcutaneous glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist conjugated to analog peptide of GLP-1.84”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1/glucagon dual agonists promote glucose and body weight reduction via regulation of hunger/appetite and increasing energy expenditure.”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mice models, pemvidutide lowered body weight and liver enzymes while promoting better blood glucose control, improved liver steatosis, inflammation and fibrosis superior to semaglutide.84”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [84]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“Semaglutide 2.4 mg once weekly is the latest approved GLP-1 RA for obesity management (2021) and results in 15 – 17% mean WL through appetite reduction [11, 12].”
InfluentialSelf-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“In SURMOUNT-1, 72 weeks of tirzepatide induced mean WL of 16 – 22.5% in people without diabetes compared to 2.4% with placebo, with no sign of the weight plateauing, suggesting that there may be further WL with long-term use [46].”
InfluentialEstruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616 · cited 1×
“…to optimise health outcomes regardless of WL – increased levels of physical activity have multiple health bene fi ts including improvement of body composition, physical function and cardiorespiratory fi tness, and a balanced Mediterranean diet may be associated with cardiovascular bene fi ts [105].”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“The SELECT trial is the fi rst study providing long-term data on the safety and ef fi cacy of semaglutide 2.4 mg [110].”
InfluentialDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 1×
“…with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as fi rst-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal bene fi ts [109].”
Self-citationTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“…has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 40 – 69% of participants achieved ≥ 10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43].”
InfluentialSelf-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“…and behavioural changes) are the cornerstone of obesity management with diverse bene fi ts, but even the most intensive lifestyle interventions result in up to 10% mean weight loss (WL) and weight maintenance remains a challenge, as 80% of WL is expected to be regained over the next 5 years [4, 5].”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“1) [17, 18].”
(2019) · Nature Communications · doi:10.1038/41467.2041-1723 · Cited by 1,914
Research works printed but not linked: 2
- Pfizer announces topline phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity | Pfizer. 2023. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
- Pfizer Provides Update on GLP-1-RA clinical development program for adults with obesity and type 2 diabetes mellitus | Pfizer. 2023. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development
Cited by
Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00355-1 · Cited by 1,151
“92 The use of anti-obesity medications for weight control is nothing new.”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Ng, M., Dai, X., Cogen, R. M., Abdelmasseh, M., Abdollahi, A., Abdullahi, A., Aboagye, R. G., Abukhadijah, H. J., Adeyeoluwa, T. E., Afolabi, A. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01548-4 · Cited by 344
“109,110 The clinical trial on semaglutide in adolescents with obesity, for instance, has found an average of 16·1% reduction in BMI among treated participants after 68 weeks.”
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
Metadata
- Authors
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J.
- Affiliations
- University of Leicester (GB)
- Corresponding author
- Papamargaritis, Dimitris
- Venue
- International Journal of Obesity
- Published
- 2024-02-01
- Volume
- 49
- Issue
- 3
- Pages
- 433-451
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC11971045
- OpenAlex
- W4391440666
- Cited by
- 332
- References
- 124
- Citations by year
- 2026: 100 · 2025: 155 · 2024: 76
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Journal of Obesity (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research (ACF-2022-11-007)
- NIHR Leicester Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity pharmacotherapy, GLP-1 receptor agonists, semaglutide, tirzepatide, GIP receptor agonist, glucagon, amylin, retatrutide, bimagrumab, weight loss, drug development pipeline, gut-brain axis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Glucagon-Like Peptides, Humans, Obesity, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is the pipeline for future medications for obesity? https://app.cochat.ai/papers/10.1038/s41366-024-01473-y
- The paper
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025). What is the pipeline for future medications for obesity? International Journal of Obesity. https://doi.org/10.1038/s41366-024-01473-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.